[Skip to Content]
[Skip to Content Landing]
Citations 0
January 5, 2000

Incorrect Wording

JAMA. 2000;283(1):57. doi:10.1001/jama.283.1.57

In the Letter entitled "Relapse of Depressive Symptoms After Discontinuing Sertraline," published in the July 28, 1999, issue of THE JOURNAL (1999;282:323-324), the financial disclosure statement for the reply letter is incomplete. The following should be added to what was published: "Drs Gelenberg, Rush, Koran, Klein, McCullough, Kocsis, Kornstein, Schatzberg, and Fawcett have served as consultants to and/or received grant support from numerous pharmaceutical companies, some of which manufacture sertraline or other selective serotonin reuptake inhibitors. In addition, Drs Gelenberg, Kocsis, and Schatzberg own stock in 1 or more companies that manufacture sertraline or other selective serotonin reuptake inhibitors, and Dr LaVange is affiliated with Quintiles Inc, a for-profit contract research organization, and in that role provides statistical consulting for many pharmaceutical companies, including Pfizer Inc."